Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models

Table 2

Correlation between IDO abundance and drug response.

cell line	IC50			IDO; Expression ()
	5-FU	Cisplatin	Gemcitabine
	[M]	[M]	[M]
HROC24	8.1	5.0	7.8	6.6
HROC50 T1 M5	2.3	n.a.	n.a.	5.6
HROC87 T0 M2	1.9	5.0	12.0	35.2
HROC113 cT0 M1	22.9	2.7	3.4	33.9
HROC212	n.a.	n.a.	n.a.	6.6
HROC257 T0 M1	19.3	9.0	10.8	61.2
HROC324	28.7	n.a.	n.a.	49.0
HROC39 T0 M2	5.0	7.3	3.4	25.0
HROC59 T1 M1	17.0	4.3	41.1	70.3
HROC46 T0 M1 #13	8.0	10.3	14.8	6.6
HROC370	4.0	n.a.	n.a.	8.8
HROC40	21.6	9.3	11.1	14.4
HROC60	7.7	6.3	6.7	52.8
HROC183	9.4	3.3	17.5	35.3
HROC278 T0 M1	n.a.	n.a.	n.a.	2.7
Pearsons r	5-FU	Cisplatin	Gemcitabine
	0.47	-0.28	0.49

HROC, Hansestadt Rostock Colon; 5-FU, 5-fluorouracil; IC, inhibitory concentration.